Bukwang Pharmaceutical

South Korea
Pharmaceutical products are developed, manufactured, and marketed in South Korea.
Request Access

About Bukwang Pharmaceutical

Bukwang Pharmaceutical is a company based in South Korea. It operates as a HealthTech, and Direct-to-Consumer (D2C). Bukwang Pharmaceutical has raised $5.2 million across 1 funding round from investors including TVM Capital Life Science. Bukwang Pharmaceutical has completed 1 acquisition, including Korea Union Pharmaceuticals. Bukwang Pharmaceutical offers products and services including Lurasidone, JM-010, SOL-804, and Legadex.

  • Headquarter South Korea
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Legal Name Bukwang Pharm Co., Ltd.
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $5.2 M (USD)

    in 1 rounds

  • Latest Funding Round
    $5.2 M (USD), Series A

    Mar 29, 2017

  • Investors
  • Employee Count
    Employee Count
  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Bukwang Pharmaceutical

Bukwang Pharmaceutical offers a comprehensive portfolio of products and services, including Lurasidone, JM-010, SOL-804, and Legadex. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Used for treating schizophrenia and bipolar depression effectively.

Developed for treating dyskinesia in Parkinson’s disease patients.

Designed for metastatic castration-resistant prostate cancer treatment.

Formulated as a liver disease treatment compound drug.

People of Bukwang Pharmaceutical
Headcount 500-1000
Employee Profiles 2
Employee Profiles
People
Hee-Won Yoo
CEO

Unlock access to complete

Teams

Unlock access to complete

Funding Insights of Bukwang Pharmaceutical

Bukwang Pharmaceutical has successfully raised a total of $5.2M through 1 strategic funding round. The most recent funding activity was a Series A round of $5.2 million completed in March 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Series A — $5.2M
  • First Round

    (29 Mar 2017)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Mar, 2017 Amount Series A - Bukwang Pharmaceutical Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Bukwang Pharmaceutical

Bukwang Pharmaceutical has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include TVM Capital Life Science. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Life Science focused early stage VC firm investing in Europe, Canada, the USA and Asia
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Bukwang Pharmaceutical

Bukwang Pharmaceutical has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Korea Union Pharmaceuticals. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Utility industry construction, inspection, and maintenance services are provided.
1956
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Bukwang Pharmaceutical

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Bukwang Pharmaceutical Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Bukwang Pharmaceutical

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Bukwang Pharmaceutical

Frequently Asked Questions about Bukwang Pharmaceutical

Where is Bukwang Pharmaceutical located?

Bukwang Pharmaceutical is headquartered in South Korea.

Is Bukwang Pharmaceutical a funded company?

Bukwang Pharmaceutical is a funded company, having raised a total of $5.2M across 1 funding round to date. The company's 1st funding round was a Series A of $5.2M, raised on Mar 29, 2017.

What does Bukwang Pharmaceutical do?

Bukwang Pharmaceutical is involved in the research, development, and production of pharmaceutical products, including prescription medicines, over-the-counter drugs, and health supplements. The company operates in the healthcare sector, focusing on innovative drug development for conditions such as schizophrenia, Parkinsons disease, and prostate cancer. Solutions are provided through a robust pipeline and open innovation strategies, aiming for global expansion as a leading pharmaceutical entity. Emphasis is placed on sustainability and ethical governance to ensure a healthier future.

What products or services does Bukwang Pharmaceutical offer?

Bukwang Pharmaceutical offers Lurasidone, JM-010, SOL-804, and Legadex.

How many acquisitions has Bukwang Pharmaceutical made?

Bukwang Pharmaceutical has made 1 acquisition, including Korea Union Pharmaceuticals.

Who are Bukwang Pharmaceutical's investors?

Bukwang Pharmaceutical has 1 investor. Key investors include TVM Capital Life Science.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available